NGNE
Neurogene Inc.
NASDAQ · USHealthcareBiotechnology
$37.34+0.08%
Price as of Jul 20, 2026
NGNE growth
Neurogene Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -100.0%
- EBITDA
- -19.8%
- EBIT
- -23.4%
- EPS
- -7.7%
- Free cash flow
- -15.9%
- Operating cash flow
- -17.5%
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -2.8%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- -21.4%
- EBIT
- -24.9%
- Net income
- -20.2%
- EPS
- +0.9%
- Free cash flow
- -9.7%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.